STN-Structure Search 5/25/08

10/525,985

=> d ibib abs hitstr 1-136

L10 ANSWER 1 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:408670 CAPLUS
TITLE: Alkaloid of lindera aggregata, its preparation and application in pharmaceutical
INVENTOR(S): Hao, Guixin; Wang, Zhengtao; Zhou, Jiyan
PATENT ASSIGNEE(S): Shanghai University of Traditional Chinese Medicine, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 14 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1762359	A	20060426	CN 2005-10030088	20050928
PRIORITY APPLN. INFO.:			CN 2005-10030088	20050928

AB The patent relates to the application of alkaloid of Lindera aggregata to prepare the medicine for treating rheumatoid arthritis and other autoimmune disease. The alkaloid of Lindera aggregata is prepared by extracting Lindera aggregata with 6-10 fold and 70-90 % at reflux temperature for 1-48 h and for three times, combining extraction solution, filtering, concentrating, adding HCl, dissolving alkaloid, filtering, adjusting pH to 8.0-10.0 with ammonia liquor, stirring, storing for 5 h, filtering to remove deposit, and reduced pressure drying at 55 ° to alkaloid of Lindera aggregata. The content of total alkaloid over 50 %, and norisoboldine over 30 %. The alkaloid contains boldine, laurolistine, reticuline, linderaline, pallidine, protosinomenine, laudanosoline-3',4'-dimethylether, pronuciferine, and norisoboldine.

IT INDEXING IN PROGRESS
IT **476-70-0**, Boldine **23599-69-1**, Norisoboldine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(alkaloid of Lindera aggregata, its preparation and application in pharmaceutical)
RN 476-70-0 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23599-69-1 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-1,9-diol, 5,6,6a,7-tetrahydro-2,10-dimethoxy-, (6aS)- (9CI) (CA INDEX NAME)

consumption of antioxidants is beneficial. However, the literature is divided in support of this conclusion. In this study, Boldine, an alkaloid of Peumus boldus and reduced form of RU486, was tested for their antioxidant potency both in, in vitro oxidation system and in mouse models. Boldine decreased the ex-vivo oxidation of low-d. lipoprotein (LDL). Two different in vivo studies were performed to study the effect of these compds. on the atherosclerotic lesion formation in LDLR-/- mice. In study I, three groups of LDLR-/- mice (N=12 each) were fed an atherogenic diet. Group 1 was given vehicle and group 2 and 3 were given 1 mg of Boldine or Red RU per day for 12 wk. In study II, two groups of LDLR-/- mice (N=10 each) were fed an atherogenic diet. Group 1 was given vehicle and group 2 was given 5 mg of Boldine per day. The results indicated that there was a decrease in lesion formation reaching a 40% reduction due to Boldine and 45% reduction by Red RU compared to controls. The in vivo tolerance of Boldine in humans (has been used as an herbal medicine in other diseases) should make it an attractive alternative to Vitamin E.

IT **476-70-0**, Boldine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(a novel alkaloid antioxidant, Boldine and synthetic antioxidant, reduced form of RU486, inhibit the oxidation of LDL in-vitro and atherosclerosis in vivo in LDLR-/- mice)

RN 476-70-0 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:220036 CAPLUS
DOCUMENT NUMBER: 140:247606
TITLE: Method to treat cardiac fibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist
INVENTOR(S): Egan, James J.; McMahon, Ellen G.; Olins, Gillian M.; Schuh, Joseph R.
PATENT ASSIGNEE(S): G.D. Searle & Co., USA
SOURCE: U.S. Pat. Appl. Publ., 146 pp., Cont.-in-part of U.S. Ser. No. 506,068, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2004053903	A1	20040318	US 2003-371699	20030221
US 6984633	B2	20060110		
PRIORITY APPLN. INFO.:			US 1995-486085	B1 19950607
			US 1997-783404	B1 19970113
			US 1997-980734	B3 19971201
			US 1998-181586	B1 19981028
			US 1999-317237	B1 19990524
			US 2000-506068	B1 20000217

OTHER SOURCE(S): MARPAT 140:247606

AB A therapeutic method is described for treating cardiac fibrosis or cardiac hypertrophy using a combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of an angiotensin II receptor antagonist. Preferred angiotensin II receptor antagonists are those compds. having high potency and bioavailability and which are characterized in having an imidazole or triazole moiety attached to a biphenylmethyl or pyridinyl/phenylmethyl moiety. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of a 9α, 11α-substituted epoxy moiety. A preferred combination therapy includes the angiotensin II receptor antagonist 5-2-[5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-pyridinyl]phenyl-1H-tetrazole and the aldosterone receptor antagonist epoxymexrenone.

IT **95508-61-5**, Isoteoline
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(method to treat cardiac fibrosis and hypertrophy with a combination therapy of an angiotensin II (AngII) antagonist and an epoxy-steroidal aldosterone antagonist)

RN 95508-61-5 CAPLUS

CN 4H-Dibenzo[de,g]quinolinediol, 5,6,6a,7-tetrahydro-2,9(or 2,10)-dimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

CM 1

CRN 95508-60-4
CMF C18 H19 N O4

Absolute stereochemistry.



CM 2

CRN 67-56-1
CMF C H4 O

H_3C-OH

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Inventors

L10 ANSWER 30 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:181940 CAPLUS
DOCUMENT NUMBER: 140:235926
TITLE: Preparation of new noraporphine derivatives for use in cosmetic and dermopharmaceutic compositions
INVENTOR(S): Lintner, Karl
PATENT ASSIGNEE(S): Sederma Sa, Fr.
SOURCE: Fr. Demande, 32 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2843963	A1	20040305	FR 2002-10810	20020830
FR 2843963	B1	20041022		
WO 2004024695	A1	20040325	WO 2003-FR2400	20030729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003288304	A1	20040430	AU 2003-288304	20030729
EP 1534682	A1	20050601	EP 2003-780203	20030729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005537332	T2	20051208	JP 2004-535571	20030729

PRIORITY APPLN. INFO.:
FR 2002-10810 A 20020830
WO 2003-FR2400 W 20030729

OTHER SOURCE(S): MARPAT 140:235926
GI



I

AB The present invention relates to new derivs. I (R1, R2, R3, R4, R5 = H, alkyl, aryl, aralkyl,acyl, sulfonyl sugar) of noraporphine, their optical isomers, their mixts. and their cosmetically acceptable salts, it also relates to all the cosmetic and dermopharmaceutic compns. which contain one or more these derivs., only or in partnership with an extract of plant, particularly the Glaucium flavum, and in particular the prepns. having for objective a reduction in the pigmentation, an anti-age effect, or thinning. Thus, 2,9-diacetoxy-1,10-dimethoxy-6-methylnoraporphine [I; R1 = R4 = Ac, R2 = R3 = R5 = Me; Ac = COMe] was prepared from 2,9-dihydroxy-1,10-dimethoxy-6-methylnoraporphine (I; R1 = R4 = H, R2 = R3 = R5 = Me) via acetylation with Ac2O in CH2Cl2 containing EtN(CHMe2)2. I (R1 = R4 = Ac, R2 = R3 = R5 = Me) was tested for its ability to inhibit lipid peroxidn. [100% @ 0.15 mmol/L] and glycerol-3-phosphate dehydrogenase [76% @ 0.09 mmol/L]. A day cream formulation containing I (R1 = R4 = Ac, R2 = R3 = R5 = Me) is described.

IT **73951-75-4P**, 2,9-Diacetoxy-1,10-dimethoxy-6-methylnoraporphine
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and bioactivity of new noraporphine derivs. for use in cosmetic and dermopharmaceutic compns.)

RN 73951-75-4 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



IT **5630-11-5**, 1,2,9,10-Tetramethoxy-6-methylnoraporphine
38849-65-9, 1,2,10-Trimethoxy-9-hydroxy-6-methylnoraporphine
RL: COS (Cosmetic use); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(preparation and bioactivity of new noraporphine derivs. for use in cosmetic and dermopharmaceutic compns.)

RN 5630-11-5 CAPLUS

CN 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 38849-65-9 CAPLUS



REFERENCE COUNT: 116 THERE ARE 116 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 45 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:808279 CAPLUS
DOCUMENT NUMBER: 135:344631
TITLE: Preparation of thaliporphine and its derivatives for treatment of cardiac diseases same
INVENTOR(S): Su, Ming-Jai; Lee, Shoei-Sheng
PATENT ASSIGNEE(S): National Science Council, Taiwan
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6313134	B1	20011106	US 2000-644932	20000823
TW 225397	B1	20041221	TW 2000-89108508	20000504
CA 2412170	AA	20020228	CA 2001-2412170	20010228
WO 2002016325	A1	20020228	WO 2001-CN304	20010228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001048226	A5	20020304	AU 2001-48226	20010228
EP 1311486	A1	20030521	EP 2001-921112	20010228
EP 1311486	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011761	A	20030624	BR 2001-11761	20010228
JP 2004506719	T2	20040304	JP 2002-521201	20010228
ZA 2002009965	A	20040309	ZA 2002-9965	20021209

PRIORITY APPLN. INFO.:
TW 2000-89108508 A 20000504
US 2000-644932 A 20000823

WO 2001-CN304 W 20010228

OTHER SOURCE(S): MARPAT 135:344631

GI



I

AB The thaliporphine derivs. I (R = H, acetyl, propionyl, butyryl, tert-butoxycarbonyl) were prepared for the treatment and/or prophylaxis of cardiac diseases, including cardiac arrhythmia, myocardial ischemia or myocardial infarction, and sudden death caused by cardiac arrhythmia or acute myocardial infarction. Thus, (+)-laurolitsine, isolated from the stem of Phoebe formosana Hayata, underwent formylation, methylation and hydrolysis to give norglaucine, which was methylated with formaldehyde and NaBH4 and then demethylated with 90% H2SO4 to give thaliporphine. 10 μM thaliporphine was effective in inhibiting cardiac arrhythmic induced in the isolated guinea pig heart subjected to global ischemic followed by reperfusion.

IT **5083-88-5P**, Thaliporphine **371196-14-4P**, (+)-N-Propylthaliporphine **371196-20-2P 371196-21-3P 371196-22-4P 371196-23-5P 371196-24-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thaliporphine and derivs. for treatment of cardiac disease)

RN 5083-88-5 CAPLUS

CN 4H-Dibenzo[de,g]quinolin-1-ol, 5,6,6a,7-tetrahydro-2,9,10-trimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 371196-14-4 CAPLUS

CN 4H-Dibenzo[de,g]quinolin-1-ol, 5,6,6a,7-tetrahydro-2,9,10-trimethoxy-6-propyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371196-20-2 CAPLUS
CN 4H-Dibenzo[de,g]quinolin-1-ol, 5,6,6a,7-tetrahydro-2,9,10-trimethoxy-6-[2-(2-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 371196-21-3 CAPLUS
CN 4H-Dibenzo[de,g]quinolin-1-ol, 5,6,6a,7-tetrahydro-2,9,10-trimethoxy-6-[2-(2-methoxyphenoxy)ethyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 371196-22-4 CAPLUS
CN 4H-Dibenzo[de,g]quinolin-1-ol, 5,6,6a,7-tetrahydro-2,9,10-trimethoxy-6-[2-(2-methoxyphenoxy)ethyl]-, propanoate (ester) (9CI) (CA INDEX NAME)



RN 371196-23-5 CAPLUS
CN Butanoic acid, 5,6,6a,7-tetrahydro-2,9,10-trimethoxy-6-[2-(2-methoxyphenoxy)ethyl]-4H-dibenzo[de,g]quinolin-1-yl ester (9CI) (CA INDEX NAME)



RN 371196-24-6 CAPLUS
CN Carbonic acid, 1,1-dimethylethyl 5,6,6a,7-tetrahydro-2,9,10-trimethoxy-6-[2-(2-methoxyphenoxy)ethyl]-4H-dibenzo[de,g]quinolin-1-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 46 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:546294 CAPLUS
DOCUMENT NUMBER: 135:327038
TITLE: Chemopreventive activity of isoquinoline alkaloids from Corydalis plants
AUTHOR(S): Ito, Chihiro; Itoigawa, Masataka; Tokuda, Harukuni; Kuchide, Masashi; Nishino, Hoyoku; Furukawa, Hiroshi
CORPORATE SOURCE: Faculty of Pharmacy, Meijo University, Nagoya, 468-8503, Japan
SOURCE: Planta Medica (2001), 67(5), 473-475
CODEN: PLMEAA; ISSN: 0032-0943

DOCUMENT TYPE: Journal
LANGUAGE: English

AB The alkaloid (S)-(+)-1,2,9,10-tetramethoxyaporphine (glaucine) is a phosphodiesterase 4 inhibitor with bronchodilator and anti-inflammatory activity in vitro. In this study, we examined the in vivo effects of glaucine on an animal model of asthma. In ovalbumin sensitized guinea pigs, inhaled glaucine (10 mg ml-1, 3 min) inhibited the acute bronchoconstriction produced by aerosol antigen (antigen response was 256±42 and 95±14 cm H2O l-1 s-1 in control and glaucine-treated animals, resp.; P<0.05). Pretreatment with glaucine (10 mg ml-1, 10 min inhalation, 30 min pre- and 3 h post-antigen exposure) markedly reduced airway hyperreactivity to histamine, eosinophil lung accumulation, and increased eosinophil peroxidase activity in bronchoalveolar lavage fluid 24 h after exposure of conscious guinea pigs to aerosol antigen. In addition, inhaled glaucine (5-10 mg ml-1, 3 min) inhibited the microvascular leakage produced after inhaled antigen at all airway levels. These data support the potential interest of phosphodiesterase 4 inhibitors in asthma treatment.

IT **475-81-0**, Glaucine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(effects of inhaled glaucine on pulmonary responses to antigen in sensitized guinea pigs)

RN 475-81-0 CAPLUS
CN 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 61 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:342579 CAPLUS
DOCUMENT NUMBER: 132:352772
TITLE: Alkaloids of Stephania species (Menispermaceae) as chloroquine resistance-overcoming agents, and antimalarial agents containing them
INVENTOR(S): Ono, Minoru; Haruki, Kosuke
PATENT ASSIGNEE(S): Kaken Drug Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 2000143523	A2	20000523	JP 1998-311919	19981102
PRIORITY APPLN. INFO.:			JP 1998-311919	19981102

AB Antimalarial agents contain the alkaloids, their derivs., and/or their salts, and other antimalarial agents. Concomitant use of chloroquine and 0.08 μg/mL cepharanthine showed antimalarial activity against K1 strain with an IC50 of 13.2 nM, vs. 264.5 nM, without cepharanthine.

IT **70518-70-6**, Lastourvilline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antimalarial agents containing alkaloids of Stephania for chloroquine-resistant strains)

RN 70518-70-6 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-1,2-diol, 5,6,6a,7-tetrahydro-9,10-dimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 62 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2000:278957 CAPLUS
DOCUMENT NUMBER:	133:99116
TITLE:	Anticancer agents suppressive for adult parasites of filariasis in mongolian jirds
AUTHOR(S):	Kinnamon, Kenneth E.; Engle, Robert R.; Poon, Bing T.; Ellis, William Y.; McCall, John W.; Dzimianski, Michael T.
CORPORATE SOURCE:	Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, DC, 20307-5100, USA
SOURCE:	Proceedings of the Society for Experimental Biology and Medicine (2000), 224(1), 45-49 CODEN: PSEBAA; ISSN: 0037-9727
PUBLISHER:	Blackwell Science, Inc.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Eight chemical structures not previously reported to possess antifilarial activity have been identified. A total of 79 compds. with anticancer properties were evaluated for possible macrofilaricidal activity against Brugia pahangi and Acanthochelionema viteae transplanted into male Mongolian jirds (Meriones unguiculatus). All eight active compds. were suppressive for the onchocerciasis type (Acanthocheilonema viteae) of the disease. None was macrofilaricidal for the lymphatic form (Brugia pahangi). These new structures may represent a nucleus around which effective drugs can be synthesized.

IT **5373-42-2**, Thalicarpine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological

IT **475-81-0**, S-(+)-Glaucine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(glaucine mechanism of bronchodilator and antiinflammatory activities)
RN 475-81-0 CAPLUS
CN 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 66 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:420883 CAPLUS
DOCUMENT NUMBER: 131:97615
TITLE: NFκB activity inhibitors
INVENTOR(S): Baba, Masanori; Ono, Minoru
PATENT ASSIGNEE(S): Kaken Drug Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11180873	A2	19990706	JP 1997-353879	19971222
EP 931544	A2	19990728	EP 1998-104269	19980310
EP 931544	A3	20040825		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: JP 1997-353879 A 19971222

AB Alkaloids [e.g. cepharanthin and isotetrandrine] isolated from Stephania cepharantha are nuclear factor κB activity inhibitors useful for prophylactic or therapeutic use.

IT **70518-70-6**, Lastourvilline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nuclear factor κB activity inhibitors for prophylactic or therapeutic use)
RN 70518-70-6 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-1,2-diol, 5,6,6a,7-tetrahydro-9,10-dimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 67 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:233799 CAPLUS
DOCUMENT NUMBER: 130:282215
TITLE: Preparation of aporphinoid matrix metalloproteinase inhibitors
INVENTOR(S): Krell, Hans-Willi; Grams, Frank; Brunner, Alfred
PATENT ASSIGNEE(S): Roche Diagnostics G.m.b.H., Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916441	A1	19990408	WO 1998-EP6123	19980926
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9808782	A	20000327	ZA 1998-8782	19980925
AU 9897470	A1	19990423	AU 1998-97470	19980926
PRIORITY APPLN. INFO.:			EP 1997-116778 A	19970926
			WO 1998-EP6123 W	19980926

OTHER SOURCE(S): MARPAT 130:282215
GI



I



II

AB Aporphine derivs. I [R1 = H, OH, acyl, halogen, alkyl; R2 = H, OH, CN, alkyl, acyl; R3, R4 = H, OH, acyl, halogen, alkyl; R3R4 = fused ring; R5, R6 = H, OH, SH, acyl, halogen, alkyl, alkoxy; R7 = H, OH, halogen, amino; R8 = H, OH, SH, acyl, halogen, alkyl; R9 = H, OH, SH, alkoxy, alkylthio; R8R9 = O-(CH2)n-O; n = 1, 2; R10 = H, OH, SH, acyl, halogen, amino, alkyl] were prepared as matrix metalloproteinase (MMP) inhibitors for the treatment of diseases where MMP activity is involved. Thus, aporphine II was prepared by reacting EtI with 1,10-dimethoxyaporphine-2,9-diol in DMF using K2CO3. Prepared compds. were tested for MMP-2, -3, -8, and -9 inhibitory activity.

IT **475-81-0P**, Glaucine **476-70-0P**, Boldine
222557-68-8P 222557-70-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(aporphinoid matrix metalloproteinase inhibitors)

RN 475-81-0 CAPLUS

CN 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 476-70-0 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222557-68-8 CAPLUS
CN 4H-Dibenzo[de,g]quinolin-2-ol, 9-ethoxy-5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 222557-70-2 CAPLUS
CN 4H-Dibenzo[de,g]quinolin-9-ol, 2-butoxy-5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 68 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:217643 CAPLUS
DOCUMENT NUMBER: 130:217510
TITLE: Recent developments in the chemistry and pharmacology of boldo and boldine
AUTHOR(S): Cassels, Bruce K.
CORPORATE SOURCE: Department of Chemistry, Facultad de Ciencias, Universidad de Chile, Santiago, Chile
SOURCE: Chemistry, Biological and Pharmacological Properties



● I^-

RN 22267-73-8 CAPLUS
CN 4H-Dibenzo[de,g]quinolinium, 6-ethyl-5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I^-

L10 ANSWER 133 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:94521 CAPLUS
DOCUMENT NUMBER: 68:94521
TITLE: Comparative pharmacological investigation of some alkaloids of the aporphine group
AUTHOR(S): Berezhinskaya, V. V.; Aleshinskaya, E. E.; Aleshkina, Ya. A.
CORPORATE SOURCE: Vses. Nauch.-Issled. Inst. Lek. Rast., Moscow, USSR
SOURCE: Farmakologiya i Toksikologiya (Moscow) (1968), 31(1), 44-6
CODEN: FATOAO; ISSN: 0014-8318
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Glaucine, bulbocapnine, corydine, and isocorydine all exhibited adrenolytic action in anesthetized cats and rabbits. Glaucine was the most active adrenolytic agent of the 4 aporphine alkaloids. Unlike the others, when administered in tolerable doses, glaucine exhibited strong antitussive properties but did not cause catalepsy. Glaucine was the only

compound in this group which did not contain at least 1 free OH group, and its distinct pharmacol. action may be related to this mol. structural variation.

IT **475-81-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(sympatholytic activity of)

RN 475-81-0 CAPLUS

CN 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 134 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1968:20793 CAPLUS

DOCUMENT NUMBER: 68:20793

TITLE: Pharmacological study of methiodides of O-methyl-isocorydine and thalicmidine

AUTHOR(S): Shakhabutdinova, Kh. S.; Kamilov, I. K.; Fakhrutdinov, S. F.

SOURCE: Meditsinskii Zhurnal Uzbekistana (1967), (5), 36-9
CODEN: MZUZA8; ISSN: 0025-830X

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB The effect of these compds. was investigated on white mice and on rabbits. Small s.c. doses of both prepns. provoked a motility restriction of short duration. Average doses of 5-9 mg./kg. of body weight of O-methylisocorydine (I)
and of 100-350 mg./kg. of thalicmidine (II) caused motility disturbances, occasional head trembling, forced respiration, convulsions, and finally (in some animals) a definite stop of breathing. These signs were evident for 45-70 min., the status of the animals then becoming normal. The absolute s.c. LD of I is 11 mg./kg., and that of II is 450 mg./kg. Much smaller doses are needed by i.v. application: 5 mg. I/kg. and 10 mg. II/kg. The death of all exptl. animals follows 10-40 sec. later. Tolerable doses provoke an inapparent weakening of muscle strength in the lower extremities. Average doses elevate the amplitude of respiratory movements and accelerate the frequency of these movements, the influence on respiration being more pronounced with the methiodide of II. Relatively small differences in the structure of quaternary derivs. of both I and II provoke distinctly different biol. results. I has a much greater toxicity than the methiodide of II. The intensity and duration of their hypotensive activity differ, and are dependent on the dose of the alkaloid. Small doses of II methiodide induce a distinct fall of blood pressure, but the effect of I is a much more protracted one. 9 references.

IT **18482-48-9**

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (pharmacology of)
RN 18482-48-9 CAPLUS
CN 4H-Dibenzo[de,g]quinolinium, 5,6,6a,7-tetrahydro-1-hydroxy-2,9,10-trimethoxy-6,6-dimethyl-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I^-

L10 ANSWER 135 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1967:498890 CAPLUS
DOCUMENT NUMBER: 67:98890
TITLE: Additional pharmacological properties of some quaternary glaucine derivatives
AUTHOR(S): Donev, N.
SOURCE: Trudove na Nauchnoizsledovatelskiya Khimikofarmatsevtichen Institut (1966), 5, 92-8
CODEN: TKZGAG; ISSN: 0371-8972
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian
AB The pharmacol. effect was studied of glaucine.PrI (2,3,5,6-tetramethoxyaporphine.PrI) (I) and glaucine.PhCH2Cl (II) on respiration, autonomous nervous system, and smooth muscle in cats, rabbits, and mice. Aqueous solns. were injected i.v. The LD50 of I was 0.25 and of II 0.24 g./kg. No effect on respiration was observed. The blood pressure fell by 50% at 0.0005 g./kg. of I or II. The pressor effect of adrenaline was potentiated. The hypotensive effect of atropine and the depressor effect of acetylcholine and vagus were considerably decreased. Mild spasmolytic activity on an isolated intestine was observed.
IT **17459-99-3 17460-00-3**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (pharmacology of)
RN 17459-99-3 CAPLUS
CN 6aα-Aporphinium, 1,2,9,10-tetramethoxy-6-propyl-, iodide (8CI) (CA INDEX NAME)

Absolute stereochemistry.



● I^-

RN 17460-00-3 CAPLUS
CN 6aα-Aporphinium, 6-benzyl-1,2,9,10-tetramethoxy-, chloride (8CI) (CA INDEX NAME)

Absolute stereochemistry.



● Cl^-

L10 ANSWER 136 OF 136 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1967:17903 CAPLUS
DOCUMENT NUMBER: 66:17903
TITLE: Pharmacology of the alkaloid glaucine
AUTHOR(S): Aleshinskaya, E. E.; Berezhinskaya, V. V.
CORPORATE SOURCE: All-Union Sci.-Res. Inst. Med. and Aromatic Plants, Moscow, USSR
SOURCE: Farmakologiya i Toksikologiya (Moscow) (1966), 29(5), 611-15
CODEN: FATOAO; ISSN: 0014-8318
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Glaucine, from Glaucium flavum, is adrenolytic in mice and cats at 0.02 mg./kg. In addition to its antagonism to adrenaline it has antitussive properties.
IT **475-81-0**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (pharmacology of)

RN 475-81-0 CAPLUS
CN 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 14:10:04 ON 25 MAY 2006)

FILE 'REGISTRY' ENTERED AT 14:10:16 ON 25 MAY 2006
L1 STRUCTURE UPLOADED
L2 36 S L1
L3 702 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:13:53 ON 25 MAY 2006
L4 1512 S L3
L5 143 S L3/THU

FILE 'REGISTRY' ENTERED AT 14:15:24 ON 25 MAY 2006
L6 STRUCTURE UPLOADED
L7 30 S L6
L8 621 S L6 FULL

FILE 'CAPLUS' ENTERED AT 14:16:40 ON 25 MAY 2006
L9 1474 S L8
L10 136 S L8/THU

=> d l6
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr 1-12

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:901908 CAPLUS
DOCUMENT NUMBER: 143:234986
TITLE: Dermo-cosmetic compositions for depigmentation of skin and their use
INVENTOR(S): Besse, Renand
PATENT ASSIGNEE(S): Laboratoires S.V.R., Fr.
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1566168	A1	20050824	EP 2004-290479	20040223
EP 1566168	B1	20060419		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: EP 2004-290479 20040223

AB A dermo-cosmetic composition having depigmentation action on the skin comprises the combination of kojic acid esters, diacetylboldine, and undecenoylphenylalanine. A fluid gel contained dipalmitoyl kojic acid 10.0, dimethicone 1.0, glyceryl tribehenate 0.32, cyclomethicone 3.50, trihydroxy stearine (Thixogel) 16.0, isononyl isononanoate 25.0, undecenoyl phenylalanine 5.0, 0.1% diacetylboldine on neutral support 0.05, propylparaben 0.20, methylparaben 0.20, lavandin essence q.s., hydrophobic and sphingolipids 0.50 g, and water qs to 100.00 mL.

IT **72584-75-9**
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(dermo-cosmetic compns. for depigmentation of skin and their use)

RN 72584-75-9 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester), (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:931423 CAPLUS
DOCUMENT NUMBER: 141:400495
TITLE: Skin-lightening cosmetics containing boldines
INVENTOR(S): Odera, Akio; Tanabe, Hiroyuki; Masuda, Junko
PATENT ASSIGNEE(S): Croda Japan K. K., Japan

10/525,985

SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004307352	A2	20041104	JP 2003-99156	20030402

PRIORITY APPLN. INFO.: JP 2003-99156 20030402
OTHER SOURCE(S): MARPAT 141:400495
GI



I

AB The cosmetics, which show low skin irritation, contain boldines I (n may be 1-8). A cream containing 0.004 weight% I showed good skin color-lightening effect.

IT **73951-75-4**
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(skin-lightening cosmetics containing boldines)

RN 73951-75-4 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:743699 CAPLUS
DOCUMENT NUMBER: 142:341426
TITLE: LUMISKIN: a new mechanism for reducing skin pigmentation
AUTHOR(S): Lintner, Karl

CORPORATE SOURCE: Sederma SAS, UK
SOURCE: Research Disclosure (2004), 480(April), P418-P419 (No. 480011)
CODEN: RSDSBB; ISSN: 0374-4353
PUBLISHER: Kenneth Mason Publications Ltd.
DOCUMENT TYPE: Journal; Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RD 480011		20040410		

PRIORITY APPLN. INFO.: RD 2004-480011 20040410

AB Enhanced understanding of the process of melanogenesis, and, in particular, the upstream pathways of tyrosinase regulation, have enabled discovery of new active substances called LUMISKIN. The development of LUMISKIN (diacetyl boldine) was based on regulation of tyrosinase activity via two key factors: calcium influx and the stabilization of the inactive form of tyrosinase. The efficacy of LUMISKIN has been demonstrated both in vitro and in vivo studies.

IT **72584-75-9**, Lumiskin
RL: BSU (Biological study, unclassified); COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(efficacy of LUMISKIN (diacetyl boldine) for reducing skin pigmentation)

RN 72584-75-9 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester), (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:460358 CAPLUS
DOCUMENT NUMBER: 141:248346
TITLE: Di-acetyl-nor-aporphines: novel molecules and novel mechanism to inhibit melanogenesis
AUTHOR(S): Mas-Chamberlin, C.; Peschard, O.; Leroux, R.; Mondon, Ph.; Lamy, F.; Lintner, K.
CORPORATE SOURCE: Fr.
SOURCE: SOFW Journal (2004), 130(3), 2, 4-8, 10
CODEN: SOFJEE; ISSN: 0942-7694
PUBLISHER: Verlag fuer Chemische Industrie H. Ziolkowsky
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Nor-aporphine derivs. have been discovered which interfere with the intra- and extracellular calcium flux. It has been shown that adrenergic antagonists that block the Calcium exchange lead to an inhibition of the phospholipase C/IP3/PKC cascade, thus blocking tyrosinase activation.

Di-acetyl-dimethoxy-methyl-nor-aporphine was a semi-synthetic mol. of natural origin with very high potency. On B16 melanocytes as well as in normal human melanocytes the decrease in melanin synthesis reached .apprx.50% at a level of 40 ppm in the culture medium. On a molar concentration basis, this was 50 to 70 times stronger than Kojic acid inhibition. Yet, the cell viability was not affected. Reversibility studies showed that after washing out of the active compound, melanogenesis returns to normal levels. Possible mechanisms of the activity were discussed. Tests carried out on SkinEthic three-dimensional models of the epidermis and in vivo clin. studies on Asian population confirmed the strong inhibition of melanogenesis. Safety evaluation of these mols., on the other hand, demonstrated good skin tolerance and absence of toxicity.

IT **73951-75-4**
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(mechanism of skin lightening di-acetyl-nor-aporphines to inhibit melanogenesis)

RN 73951-75-4 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:181940 CAPLUS
DOCUMENT NUMBER: 140:235926
TITLE: Preparation of new noraporphine derivatives for use in cosmetic and dermopharmaceutic compositions
INVENTOR(S): Lintner, Karl
PATENT ASSIGNEE(S): Sederma Sa, Fr.
SOURCE: Fr. Demande, 32 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2843963	A1	20040305	FR 2002-10810	20020830
FR 2843963	B1	20041022		
WO 2004024695	A1	20040325	WO 2003-FR2400	20030729

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003288304	A1	20040430	AU 2003-288304	20030729
EP 1534682	A1	20050601	EP 2003-780203	20030729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005537332	T2	20051208	JP 2004-535571	20030729
PRIORITY APPLN. INFO.:			FR 2002-10810 A	20020830
			WO 2003-FR2400 W	20030729

OTHER SOURCE(S): MARPAT 140:235926

GI



I

AB The present invention relates to new derivs. I (R1, R2, R3, R4, R5 = H, alkyl, aryl, aralkyl,acyl, sulfonyl sugar) of noraporphine, their optical isomers, their mixts. and their cosmetically acceptable salts, it also relates to all the cosmetic and dermopharmaceutic compns. which contain one or more these derivs., only or in partnership with an extract of plant, particularly the Glaucium flavum, and in particular the prepns. having for objective a reduction in the pigmentation, an anti-age effect, or thinning. Thus, 2,9-diacetoxy-1,10-dimethoxy-6-methylnoraporphine [I; R1 = R4 = Ac, R2 = R3 = R5 = Me; Ac = COMe] was prepared from 2,9-dihydroxy-1,10-dimethoxy-6-methylnoraporphine (I; R1 = R4 = H, R2 = R3 = R5 = Me) via acetylation with Ac2O in CH2Cl2 containing EtN(CHMe2)2. I (R1 = R4 = Ac, R2 = R3 = R5 = Me) was tested for its ability to inhibit lipid peroxidn. [100% @ 0.15 mmol/L] and glycerol-3-phosphate dehydrogenase [76% @ 0.09 mmol/L]. A day cream formulation containing I (R1 = R4 = Ac, R2 = R3 = R5 = Me) is described.

IT **73951-75-4P**, 2,9-Diacetoxy-1,10-dimethoxy-6-methylnoraporphine
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and bioactivity of new noraporphine derivs. for use in cosmetic and dermopharmaceutic compns.)

RN 73951-75-4 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:807701 CAPLUS
DOCUMENT NUMBER: 123:314219
TITLE: A novel ring cleavage and recyclization of N-cyanomethyl-1,2,3,4-tetrahydroisoquinolinium methiodides: a biomimetic synthesis of litebamine
AUTHOR(S): Hara, Hiroshi; Kaneko, Ken-ichi; Endoh, Masaki; Uchida, Hideharu; Hoshino, Osamu
CORPORATE SOURCE: Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan
SOURCE: Tetrahedron (1995), 51(37), 10189-204
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:314219

AB Treatment of N-cyanomethyl-6-hydroxy-1,2,3,4-tetrahydroisoquinolinium methiodide with NaOMe in MeOH caused C(1)-N fission and simultaneous recyclization to give 8-hydroxy-5-methoxymethyl-1,2,3,4-tetrahydroisoquinoline. This rearrangement was used in the synthesis of litebamine.

IT **72584-75-9P 169900-87-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(biomimetic synthesis of litebamine)

RN 72584-75-9 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester), (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169900-87-2 CAPLUS
CN 4H-Dibenzo[de,g]quinolinium, 2,9-bis(acetyloxy)-6-(cyanomethyl)-5,6,6a,7-

tetrahydro-1,10-dimethoxy-6-methyl-, iodide, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I^-

IT **170081-61-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(biomimetic synthesis of litebamine)
RN 170081-61-5 CAPLUS
CN 4H-Dibenzo[de,g]quinolinium, 2,9-bis(acetyloxy)-5,6,6a,7-tetrahydro-1,10-dimethoxy-6,6-dimethyl-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I^-

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:78604 CAPLUS
DOCUMENT NUMBER: 114:78604
TITLE: Alkaloids of the Annonaceae. Part 95. Trivalvone, a new bisaporphine from bark of Trivalvaria macrophylla
AUTHOR(S): Cortes, Diego; Davoust, Daniel; Hadi, A. Hamid A.; Myint, Saw Hla; Hocquemiller, Reynald; Cave, Andre
CORPORATE SOURCE: Fac. Med. Pharm., Univ. Rouen, Saint Etienne du Rouray, 76800, Fr.
SOURCE: Journal of Natural Products (1990), 53(4), 862-6
CODEN: JNPRDF; ISSN: 0163-3864
DOCUMENT TYPE: Journal

LANGUAGE: French
GI



I



II

AB Stem bark of T. macrophylla contained trivalone (I), which is the first example of a bisaporphine dimer alkaloid with only one 1-oxoquinoid monomer. The structure of trivalvone was elucidated by 1H NMR at 400 MHz and 13C NMR at 100 MHz. In addition, 11 isoquinoline alkaloids were isolated from T. macrophylla: 1 known bisdehydroaporphine (N-methylurabaine), 1 new (norisocorytuberine; II) and 6 known aporphines (isocorytuberine, norcorydine, laurolitsine, boldine, anonaine, and nornuciferine), and 3 known oxoaporphine alkaloids (liriodenine, lysicamine, and oxostephanine). Diagnostic chemical shift data (1H NMR) for 6 tetrasubstituted aporphine alkaloids in CDCl3 and C5D5N are reported.

IT **72584-75-9**
RL: PRP (Properties)
(NMR of)

RN 72584-75-9 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester), (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:164706 CAPLUS
DOCUMENT NUMBER: 104:164706
TITLE: Combined enzymic and chemical synthesis of N-methyllaurotetanine
AUTHOR(S): Rosazza, John P.; Reeg, Scot; Yang, Li Ming
CORPORATE SOURCE: Coll. Pharm., Univ. Iowa, Iowa City, IA, 52242, USA
SOURCE: Enzyme and Microbial Technology (1986), 8(3), 161-5
CODEN: EMTED2; ISSN: 0141-0229
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The lipase of Candida cylindraceae was used to facilitate a combined enzymic-chemical synthesis of the alkaloid, N-methyllaurotetanine. The basis for this synthesis is the regioselective enzymic hydrolysis of the acetate ester functional group at the 2-position of diacetylboldine. Optimal esterase conditions for the yeast enzyme were established with p-nitrophenyl acetate as substrate and these were used in the hydrolysis of the alkaloid diacetate. The synthetic pathway described illustrates the value of enzymes as reagents in synthetic organic chemical

IT **101554-39-6P**
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and enzymic hydrolysis of)

RN 101554-39-6 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester), hydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:487491 CAPLUS

DOCUMENT NUMBER: 101:87491

TITLE: 6a,7-Dehydroboldine from the bark of Peumus boldus

AUTHOR(S): Urzua, Alejandro; Torres, Rene

CORPORATE SOURCE: Fac. Cienc., Univ. Santiago, Santiago, Chile

SOURCE: Journal of Natural Products (1984), 47(3), 525-6
CODEN: JNPRDF; ISSN: 0163-3864

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The isolation and characterization of 6a,7-dehydroboldine, a minor component of the phenolic alkaloid fraction from bark of P. boldus, is reported.

IT **78178-93-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 78178-93-5 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6-dihydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:443422 CAPLUS
DOCUMENT NUMBER: 95:43422
TITLE: Isoquinoline alkaloids. XVII. Oxidation of aporphines by triplet benzophenone
AUTHOR(S): Castedo, Luis; Iglesias, Teresa; Puga, Alberto; Saa, Jose M.; Suau, Rafael
CORPORATE SOURCE: Fac. Quim., Inst. Prod. Nat. Org., Santiago de Compostela, Spain
SOURCE: Heterocycles (1981), 15(2), 915-18
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Nonphenolic and phenolic aporphine and noraporphine alkaloids were dehydrogenated by triplet benzophenone. It is based on the photoredn. of Ph2CO by amines. Thus, (+)-glaucine was irradiated in a pyridine/H2O solution containing Ph2CO to give 75% dehydroglaucine (I).

IT **72584-75-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(dehydrogenation of, with triplet benzophenone)

RN 72584-75-9 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester), (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **78178-93-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 78178-93-5 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6-dihydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:426596 CAPLUS
DOCUMENT NUMBER: 93:26596
TITLE: Studies on tetrahydroisoquinolines. XVI. Preparation of 2-hydroxyaporphines via o-quinol acetates
AUTHOR(S): Hoshino, Osamu; Ohtani, Minoru; Umezawa, Bunsuke
CORPORATE SOURCE: Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1979), 27(12), 3101-5
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB Pb(OAc)4 treatment of benzylisoquinolines I (R = R1 = Me; RR1 = CH2; R = Me, R1 = PhCH2; R = PhCH2, R1 = Me) yielded II, acetylation of which yielded aporphines III (R = R1 = Me, R2 = Ac (IV); RR1 = CH2, R2 = Ac (V); R = Me, R1 = R2 = Ac (VI); R = R2 = Ac, R1 = Me) (VII). Alkaline hydrolysis of IV-VII yielded III [(R = R1 = Me, R2 = H) (predicentrine) (VIII); (RR1 = CH2, R2 = H) (isodomesticine) (IX); (R = Me, R1 = R2 = H) (boldine); (R = R2 = H, R1 = Me)]. Methylation of VIII and IX by CH2N2 yielded III (R = R1 = R2 = Me; RR1 = CH2, R2 = Me).

IT **73951-75-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alkaline hydrolysis of)

RN 73951-75-4 CAPLUS

CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



IT **73910-73-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 73910-73-3 CAPLUS

CN 4H-Dibenzo[de,g]quinolinium, 2,9-bis(acetyloxy)-5,6,6a,7-tetrahydro-1,10-dimethoxy-6,6-dimethyl-, iodide (9CI) (CA INDEX NAME)



● I^-

L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:76745 CAPLUS
DOCUMENT NUMBER: 92:76745
TITLE: The carbon-13 NMR spectra of aporphine alkaloids
AUTHOR(S): Jackman, L. M.; Trewella, J. C.; Moniot, J. L.; Shamma, M.; Stephens, Richard L.; Wenkert, Ernest; Leboeuf, Michel; Cave, Andre
CORPORATE SOURCE: Dep. Chem., Pennsylvania State Univ., University Park, PA, 16802, USA
SOURCE: Journal of Natural Products (1979), 42(5), 437-49
CODEN: JNPRDF; ISSN: 0163-3864
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Carbon-13 NMR spectra of 21 aporphine alkaloids were analyzed and resonance bands assigned by means of spin-spin multiplicities, coupling constant and virtual coupling data, selective and single frequency off-resonance double irradiation techniques, and spin lattice relaxation times. The chemical shifts of the twelve aromatic C atoms were correlated with the types of O substitution.
IT **72584-75-9**
RL: PRP (Properties)
(carbon-13 NMR of)
RN 72584-75-9 CAPLUS
CN 4H-Dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, diacetate (ester), (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.